Compare · BFRG vs NVO
BFRG vs NVO
Side-by-side comparison of Bullfrog AI Holdings Inc. (BFRG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BFRG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 18619.3x BFRG ($12.0M).
- Over the past year, BFRG is down 54.7% and NVO is down 21.8% - NVO leads by 32.9 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for BFRG).
- NVO has more recent analyst coverage (25 ratings vs 0 for BFRG).
- Company
- Bullfrog AI Holdings Inc.
- Novo Nordisk A/S
- Price
- $0.68+0.87%
- $50.31-2.25%
- Market cap
- $12.0M
- $222.81B
- 1M return
- -0.86%
- +15.47%
- 1Y return
- -54.72%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BFRG
- SEC Form 424B3 filed by Bullfrog AI Holdings Inc.
- Bullfrog AI Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Hanson Jason David
- SEC Form 4 filed by Director Elsey R Don
- SEC Form 4 filed by Director Enright William
- SEC Form EFFECT filed by Bullfrog AI Holdings Inc.
- BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
- SEC Form S-1 filed by Bullfrog AI Holdings Inc.
- SEC Form 10-Q filed by Bullfrog AI Holdings Inc.
- SEC Form DEFA14A filed by Bullfrog AI Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S